SunTrust Banks set a $20.00 target price on American Renal Associates (NYSE:ARA) in a report issued on Thursday morning. The firm currently has a buy rating on the stock. SunTrust Banks also issued estimates for American Renal Associates’ Q4 2017 earnings at $0.15 EPS, FY2017 earnings at $0.56 EPS, Q1 2018 earnings at $0.10 EPS, Q2 2018 earnings at $0.18 EPS, Q3 2018 earnings at $0.19 EPS, Q4 2018 earnings at $0.22 EPS, FY2018 earnings at $0.69 EPS, Q1 2019 earnings at $0.15 EPS, Q2 2019 earnings at $0.21 EPS, Q3 2019 earnings at $0.23 EPS and FY2019 earnings at $0.82 EPS.

Several other analysts also recently weighed in on ARA. Zacks Investment Research downgraded shares of American Renal Associates from a buy rating to a hold rating in a research note on Friday, November 17th. Leerink Swann reissued an outperform rating and issued a $17.00 price target (down from $22.00) on shares of American Renal Associates in a research note on Tuesday, November 21st. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of Buy and an average price target of $18.25.

Shares of American Renal Associates (ARA) opened at $17.05 on Thursday. American Renal Associates has a fifty-two week low of $9.91 and a fifty-two week high of $23.30. The company has a current ratio of 1.16, a quick ratio of 1.13 and a debt-to-equity ratio of 3.57. The stock has a market cap of $528.54, a price-to-earnings ratio of -51.67, a PEG ratio of 1.49 and a beta of 4.29.

American Renal Associates (NYSE:ARA) last posted its quarterly earnings data on Tuesday, November 14th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.16 by $0.03. American Renal Associates had a negative net margin of 2.15% and a positive return on equity of 15.80%. The company had revenue of $187.71 million during the quarter, compared to the consensus estimate of $194.60 million. During the same period in the previous year, the firm posted $0.28 EPS. The firm’s revenue was down 2.7% compared to the same quarter last year. research analysts predict that American Renal Associates will post 0.56 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of the company. Van Berkom & Associates Inc. increased its position in shares of American Renal Associates by 490.5% during the third quarter. Van Berkom & Associates Inc. now owns 2,191,863 shares of the company’s stock valued at $32,812,000 after buying an additional 1,820,649 shares during the period. TimesSquare Capital Management LLC increased its position in shares of American Renal Associates by 6.7% during the second quarter. TimesSquare Capital Management LLC now owns 1,290,200 shares of the company’s stock valued at $23,933,000 after buying an additional 80,650 shares during the period. Vanguard Group Inc. grew its holdings in American Renal Associates by 7.9% in the second quarter. Vanguard Group Inc. now owns 1,002,294 shares of the company’s stock worth $18,593,000 after purchasing an additional 73,526 shares during the period. State Street Corp grew its holdings in American Renal Associates by 5.2% in the second quarter. State Street Corp now owns 146,039 shares of the company’s stock worth $2,709,000 after purchasing an additional 7,244 shares during the period. Finally, Northern Trust Corp grew its holdings in American Renal Associates by 33.4% in the second quarter. Northern Trust Corp now owns 143,693 shares of the company’s stock worth $2,666,000 after purchasing an additional 35,965 shares during the period. 93.27% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This news story was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://theolympiareport.com/2017/12/24/suntrust-banks-reiterates-20-00-price-target-for-american-renal-associates-ara.html.

About American Renal Associates

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.